In acute myeloid leukemia (AML), therapy resistance frequently occurs, leading to high mortality among patients. However, the mechanisms that render leukemic cells drug resistant remain largely undefined. Here, we identified loss of the histone methyltransferase EZH2 and subsequent reduction of histone H3K27 trimethylation as a novel pathway of acquired resistance to tyrosine kinase inhibitors (TKIs) and cytotoxic drugs in AML. Low EZH2 protein levels correlated with poor prognosis in AML patients. Suppression of EZH2 protein expression induced chemoresistance of AML cell lines and primary cells in vitro and in vivo. Low EZH2 levels resulted in derepression of HOX genes, and knockdown of HOXB7 and HOXA9 in the resistant cells was sufficient to improve sensitivity to TKIs and cytotoxic drugs. The endogenous loss of EZH2 expression in resistant cells and primary blasts from a subset of relapsed AML patients resulted from enhanced CDK1-dependent phosphorylation of EZH2 at Thr487. This interaction was stabilized by heat shock protein 90 (HSP90) and followed by proteasomal degradation of EZH2 in drug-resistant cells. Accordingly, inhibitors of HSP90, CDK1 and the proteasome prevented EZH2 degradation, decreased HOX gene expression and restored drug sensitivity. Finally, patients with reduced EZH2 levels at progression to standard therapy responded to the combination of bortezomib and cytarabine, concomitant with the re-establishment of EZH2 expression and blast clearance. These data suggest restoration of EZH2 protein as a viable approach to overcome treatment resistance in this AML patient population. a r t i c l e s 7 0 VOLUME 23 | NUMBER 1 | JANUARY 2017 nature medicine non-Hodgkin lymphomas 19 . In solid tumors, targeting EZH2 can cause regression of tumor cell growth 18 . Here, we show that loss of EZH2 induces chemoresistance toward multiple drugs in AML. We describe a post-translational mechanism of EZH2 suppression that frequently occurs in relapsed AML. Our findings indicate that inhibition of EZH2 degradation in combination with chemotherapy and/or TKIs may be a promising therapeutic approach in drug-resistant AML.
RESULTS
Loss of EZH2 associates with poor prognosis and chemoresistance in AML To evaluate the prognostic impact of EZH2 in AML, we analyzed EZH2 protein levels in 124 patients with AML (Supplementary Table 1 ) using tissue microarrays (TMAs). The absence of EZH2 protein expression, as revealed by immunohistochemical staining, correlated significantly with poor overall survival (median 9.6 versus 47.6 months, P = 0.008; Fig. 1a) , poor event-free survival (median 4.06 versus 46 months, P = 0.005; Fig. 1a ) and poor relapse-free survival (median 11.3 versus 55.3 months, P = 0.047; data not shown). Similar findings were obtained for H3K27me3 levels, which are reduced as a result of low EZH2 activity (Fig. 1b) . H3K27me3 intensity and EZH2 protein expression were closely associated in AML patient samples (P < 0.0001, Supplementary Fig. 1a) . In a Cox regression analysis, a combined score of low EZH2 protein expression and low H3K27me3 level remained an independent prognostic parameter in multivariate analysis (P = 0.018, Supplementary Fig. 1b) . Low EZH2 mRNA expression, as analyzed by qRT-PCR, also associated with poorer event-free survival (P = 0.04, Supplementary Fig. 1c , Supplementary Table 2) . A trend toward worse overall survival was also observed (P = 0.096, Supplementary Fig. 1c ). Similar findings were observed in published microarray and RNA-sequencing (RNA-seq) data sets ( Supplementary Fig. 1d,e) . EZH2 is located on chromosome 7 at location 7q31.6, and loss of the chromosomal arm 7q correlates with poor prognosis in myeloid malignancies 20 . Accordingly, deletion of chromosome 7 or of 7q in AML blasts was associated with decreased EZH2 mRNA and protein levels ( Supplementary Fig. 1f) .
In matched diagnosis-relapse AML specimens, a reduction of EZH2 protein and H3K27me3 levels was observed in 45% of the relapse samples ( Fig. 1c and Supplementary Fig. 1g ). Two patients without EZH2 loss but with reduced H3K27me3 carried an ASXL1 mutation at relapse that is also known to be associated with reduced H3K27me3 (ref. 21) (Supplementary Table 3 ). As a subset of AML patients lost EZH2 protein expression during disease progression, we investigated the possibility of a functional connection between low EZH2 levels and chemoresistance. We exposed primary AML cells with normal karyotype (Supplementary Table 4 ) to DZNep, a H3K27 methyltransferase inhibitor reported to reduce EZH2 protein levels in AML cells 22 . DZNep pretreatment, as well as simultaneous application, induced resistance to the standard chemotherapeutic agent cytarabine (AraC) ( Fig. 1d and Supplementary Fig. 1h ). An inverse correlation between EZH2 protein levels and AraC IC 50 values was observed (r = −0.94, P = 0.0005, Fig. 1d ). In line with this, knockdown of EZH2 in several AML cell lines consistently induced AraC resistance, with an average fivefold increase in IC 50 values as compared to control cells (Fig. 1e) .
Loss of EZH2 induces drug resistance in vitro and in vivo
In a complementary line of research, we investigated the mechanisms of TKI resistance in the FLT3-ITD-positive AML cell line MV4-11, which was generated by prolonged exposure to increasing doses of the multi-target protein kinase inhibitor PKC412 (ref. 23 ). The PKC412-resistant MV4-11R cells were cross-resistant to other TKIs such as AC220 but also to the standard chemotherapeutic agents cytarabine (AraC) and daunorubicin ( Fig. 2a and Supplementary  Fig. 2a ). These findings pointed toward a generalized drug resistance mechanism. Notably, EZH2 protein levels were lower in MV4-11R cells than in the parental MV4-11 cells (Fig. 2a) . The simultaneous decrease of SUZ12 and EED, the two other main components of the PRC2 complex, suggested destabilization of the complex (Fig. 2a) . Accordingly, a strong decrease of H3K27me3 was observed in resistant cells (Fig. 2a) . Exome sequencing did not reveal mutations of EZH2 that could explain the reduced protein levels in resistant cells. Instead, the FLT3 N676K mutation, as well as TP53 mutations-both known to affect drug sensitivity 24, 25 -were identified in MV4-11R cells (Supplementary Table 5 ). But neither introduction of the FLT3 N676K mutation nor shRNA-mediated knockdown of TP53 in parental MV4-11 cells increased drug resistance to the same extent as knockdown of EZH2, which induced a generalized drug resistance ( Fig. 2b and Supplementary Fig. 2b-d) . However, simultaneous knockdown of EZH2 and TP53 showed additive effects on resistance to AraC (Supplementary Fig. 2e ). Exposure to EZH2 inhibitors (GSK126, SAH-EZH2, DZNep) also induced drug resistance in sensitive parental MV4-11 cells (Supplementary Fig. 2f ) as well as in FLT3-ITD-positive primary AML blasts (Supplementary Fig. 2g ). Of note, drug resistance induced by shRNA-mediated EZH2 knockdown could be reverted by overexpression of a codon-usage-modified EZH2 mRNA (Supplementary Fig. 2h ). We transplanted MV4-11 control and EZH2 knockdown cells expressing firefly luciferase into NOD-SCID-IL2Rγ null (NSG) mice by intravenous injection. Mice were treated with PKC412 (75 mg per kg body weight per day) or vehicle daily for 9 d. In vivo PKC412 treatment suppressed the growth of MV4-11 control cells, whereas EZH2 knockdown cells were resistant to PKC412 treatment, as monitored by bioluminescence imaging (BLI) (Fig. 2c and Supplementary Fig. 2i , **P = 0.0022, ***P = 0.0001, ****P < 0.0001). Further, intravenous transplantation of either MV4-11 control or EZH2 knockdown cells in NSG mice followed by treatment with AC220 or vehicle for 10 d led to a significantly prolonged survival of AC220-treated mice transplanted with control cells, as compared to AC220-treated mice transplanted with EZH2 knockdown cells (Supplementary Fig. 2j , P = 0.0003).
HOX genes are deregulated in resistant AML cells with loss of EZH2 We next explored the downstream consequences of reduced EZH2 protein levels. In mRNA microarray analyses, we identified 202 probes corresponding to 155 genes differentially expressed between MV4-11 and MV4-11R cells, and we found a HOXA9 signature by Gene Set Enrichment Analysis (GSEA) 26 (Fig. 2d) . HOX genes encode a family of transcription factors that are highly expressed in hematopoietic stem and progenitor cells but whose expression decreases in more differentiated bone marrow cells 27 . Notably, HOX genes are targets of EZH2, as well as of MLL and MLL fusion proteins 28, 29 . Classical target genes activated by HOXA9, such as CYBB, CDK6, JUNB, FOS, CDKN1A and IGF1R, were upregulated in MV4-11R cells (data not shown). We performed chromatin immunoprecipitation followed by high-throughput DNA sequencing (ChIP-seq) for H3K27me3 to identify genomic regions affected by loss of EZH2 in MV4-11R cells. Gene ontology (GO) analysis revealed that genes affected by loss of H3K27me3 were involved in pathways such as cell fate commitment or stem cell development (Fig. 2e) . In line with the microarray expression data, promoter regions of HOX genes from different clusters Three different shRNAs were initially tested, among which shEZH2 #2 conferred the strongest knockdown (see Fig. 2b ) and was chosen for further experiments. Left, EZH2 and H3K27me3 protein expression in HL60, Kasumi-1 and ML-1 cells transduced with either shControl or shEZH2 #2. Data are representative of two independent experiments. Right, HL60, Kasumi-1 and ML-1 shControl and shEZH2 #2 cells were exposed to increasing concentrations of AraC for 72 h. MTS assays were performed to determine the percentage of proliferating cells. Means ± s.d. are shown for three independent experiments. *P = 0.033, **P < 0.001, ****P < 0.0001.
revealed drastically reduced H3K27me3 levels in the MV4-11R cells (Fig. 2f) . Several HOX genes, including HOXB7 and HOXA9, were upregulated in resistant cells at the level of mRNA and protein ( Fig. 2g and Supplementary Fig. 3a) . In an integrated analysis based on our gene expression and ChIP-seq data, H3K27me3 deposition levels inversely correlated with gene expression. In contrast, levels of H3K4me3 and H3K27ac, known as markers for active genes, positively correlated with gene expression (Supplementary Fig. 3b,c) . In total, 58 genes, including HOXB7, were differentially regulated in resistant as compared with sensitive cells when we combined mRNA expression data with H3K27me3, H3K4me3 and H3K27ac ChIP-seq data 30 ( Supplementary Fig. 3c and Supplementary Table 6 ). Differentially regulated genes were involved in hematopoiesis, myeloid cell differentiation, nucleoside and ATP binding and MHC class II pathways (Supplementary Table 7 ). H3K27me3 levels were also decreased at the promoter of the drug transporter MRP1 (encoded by the ABCC1 gene) in MV4-11R cells, with a concomitant increase in mRNA and protein levels ( Supplementary Fig. 3d,e) . In line with these results, increased drug efflux, a typical sign of drug-resistant leukemic (stem) cells, was observed in the resistant cell line (Supplementary Fig. 3f ).
High HOXB7 and HOXA9 mRNA expression levels were consistently observed in primary AML ( Supplementary Fig. 4a ), and high mRNA expression levels correlated with poor survival in the TCGA AML data set 31 ( Supplementary Fig. 4b ). Further, EZH2 expression was inversely correlated with HOXB7 and HOXA9 mRNA expression in AML (Supplementary Fig. 4c ). EZH2 knockdown in parental sensitive MV4-11 cells, as well as in the MLL-translocation-negative cell lines HL60, Kasumi-1 and ML-1, induced overexpression of HOXB7 and HOXA9 proteins, which suggested that they are regulated by EZH2 in the leukemic cells ( Supplementary Fig. 4d,e) . Importantly, knockdown of HOXB7 and HOXA9 restored drug sensitivity in MV4-11R cells and in MLL-translocation-negative AML cell lines, respectively ( Fig. 2h and Supplementary Fig. 4f,g ). The deregulation of HOX genes, as well as an increased transporter efflux, pointed toward a stem-cell-like phenotype of the resistant cells.
The CDK1-EZH2 complex is stabilized by HSP90 in drug-resistant AML cells with phosphorylation of EZH2 at threonine 487 To revert the resistance phenotype, we aimed to overexpress EZH2 in MV4-11R cells. However, lentiviral delivery of EZH2 mRNA did not restore EZH2 protein levels in the drug-resistant leukemia cells, although the same construct induced EZH2 overexpression in HEK293T cells (Supplementary Fig. 5a ). EZH2 mRNA expression, promoter DNA methylation and expression of known regulating miRNAs did not differ significantly between MV4-11 and MV4-11R cells ( Supplementary Fig. 5b-d) . These data suggest that EZH2 levels are regulated by post-translational mechanisms in resistant cells. A label-free quantitative mass spectrometry analysis of immunoprecipitated EZH2 revealed a 2.6-fold increased phosphorylation of the EZH2-residue Thr487 in resistant cells (P = 0.014, Supplementary  Fig. 5e ). Resistance-associated phosphorylation at Thr487 was confirmed by EZH2 immunoprecipitation and western blotting (Fig. 3a) . Interestingly, increased phospho-Thr487-EZH2 levels were also found in samples from the tumors of patients who had relapsed, with reduced total EZH2 seen after relapse in the matched diagnosis-relapse AML pairs ( Supplementary Fig. 5f ). Expression of a phosphorylationresistant T487A mutant of EZH2 in MV4-11R cells rescued EZH2 protein expression and increased EZH2 levels by almost ten-fold, whereas wild-type EZH2 again could not be expressed (Fig. 3b) .
The mutant T487A-EZH2 sensitized the formerly resistant cells to PKC412 (Fig. 3b) . Analysis of the amino acids in the proximity of Thr487 revealed the presence of a cyclin-dependent kinase 1 (CDK1) consensus sequence, [pS/pT]PX[R/K]. Notably, EZH2 protein levels have been shown to be regulated by CDK1-dependent phosphorylation at Thr487 in HeLa cells and human MSCs 32, 33 , priming EZH2 for ubiquitination and degradation 32 . A physical interaction between CDK1 and EZH2 was detected only in MV4-11R cells, as identified by co-immunoprecipitation (co-IP) and western blotting (Fig. 3c) . To identify the mechanism of EZH2 phosphorylation and degradation, we characterized the EZH2-CDK1 complex by SILAC (stable isotope labeling by amino acids in cell culture)-based mass spectrometry.
Immunoprecipitations with antibodies against phospho-Thr487-EZH2 and total EZH2 were performed in MV4-11R cells transduced with either empty vector or mutant T487A-EZH2. STIP1 was identified as a specific interaction partner of phosphorylated EZH2 in MV4-11R cells but was not detected in the phosphorylation-resistant T487A-EZH2 complex (Supplementary Tables 8-11 ). STIP1 (HOP) is an adaptor protein known to interact with heat-shock proteins HSP90 and HSP70 (ref. 34) . We confirmed by co-IP and western blotting that the interaction between STIP1 and EZH2 occurred in resistant but not in sensitive MV4-11 cells (Fig. 3d) . Notably, CDK1 is a known client protein stabilized by HSP90 (ref. 35 ). STIP1 and HSP90 specifically co-immunoprecipitated with CDK1 and EZH2 in MV4-11R cells, as analyzed by co-IP and western blotting (Fig. 3e) . These findings suggested that the CDK1-EZH2 interaction could be stabilized by HSP90 in the drug-resistant MV4-11R cells. In line with this hypothesis, treatment with the HSP90 inhibitor AT13387 decreased CDK1 levels and increased EZH2 protein levels as well as drug sensitivity in formerly resistant MV4-11R cells (Fig. 3f) , whereas EZH2 levels and drug sensitivity were not significantly affected in the sensitive parental MV4-11 cells (Supplementary Fig. 5g ). Furthermore, treatment of MV4-11R cells with CDK1 inhibitors increased EZH2 protein levels and drug sensitivity to PKC412 (Fig. 3f) . Inhibition of HSP90 also destabilized the CDK1-EZH2 interaction in MV4-11R cells (Fig. 3g) . Notably, in an independent drug resistance model of doxorubicin-resistant OCI-AML2 cells, we again identified loss of EZH2 in the resistant cells (Fig. 3h) . Here again, EZH2 interacted with STIP1, HSP90 and CDK1 only in the resistant cells (Fig. 3i) . HSP90-mediated stabilization of the CDK1-EZH2 complex appeared to be the predominant mechanism for increased EZH2 phosphorylation in resistant cells. Neither proliferative index, cell cycle distribution, total CDK1 activity or protein levels of cyclin B differed between sensitive and resistant cells (Supplementary Fig. 5h,i) . Nonetheless, a small contribution of cell cycle alteration cannot be entirely ruled out.
EZH2 undergoes proteasomal degradation in resistant AML, and proteasome inhibitors restore EZH2 protein levels and drug sensitivity Further SILAC-based mass spectrometry experiments identified enhanced binding of E3 ubiquitin-protein ligases and associated ubiquitin-binding proteins to EZH2 in resistant cells (Fig. 4a and Supplementary Tables 12 and 13 ). The activity of E3 ubiquitin-protein ligases has been reported to be augmented by phosphorylation of their target proteins 36 , potentially connecting CDK1-mediated Thr487 phosphorylation of EZH2 with increased E3 ligase binding and activity. Accordingly, EZH2 protein was strongly ubiquitinated in resistant but not in sensitive MV4-11 cells (Fig. 4b) . TRIM21 is an E3 ubiquitin ligase that we identified as an EZH2 binding partner with increased binding to EZH2 in resistant cells (Fig. 4a) . In line with this finding, the mass-spectrometry-based protein interaction analysis using an anti-phospho-Thr487 EZH2 antibody for pulldown of phosphorylated EZH2 confirmed that TRIM21 binding is specific for the phospho-Thr487-EZH2 in resistant cells (Supplementary Table 10) . Furthermore, treatment with proteasome inhibitors, and thereby stabilization of EZH2, led to the accumulation of TRIM21-EZH2 complexes in MV4-11R cells (Supplementary Table 14 and Fig. 4c) . These data suggest that TRIM21 may induce ubiquitination with subsequent proteasomal degradation of phospho-Thr487-EZH2. -ITD mutation (UPN 03-2-020) were exposed to vehicle or 10 nM bortezomib for 6 h. EZH2 protein levels were analyzed by western blotting (left). Vehicle-or bortezomib-pretreated AML blasts were exposed to 10 nM PKC412. Cell survival was determined by acridine orange/PI staining and cell counting from three technical replicates (*P = 0.0122, **P = 0.0056, ***P = 0.0003) (right). Immunoprecipitation data and western blots in a,b,d,e are representative of two independent experiments; data in right panels of d,e are mean ± s.d. of IC 50 values for three independent experiments (*P < 0.05, **P < 0.01). Data in g,h were analyzed by two-way ANOVA with Sidak post hoc test (**P < 0.005, ****P < 0.0001). n.s., not significant.
Notably, treatment with proteasome inhibitors such as bortezomib, a drug licensed for the treatment of multiple myeloma and mantle cell lymphoma, partially restored EZH2 protein levels and drug sensitivity in resistant MV4-11R, as well as in resistant OCI-AML2R, but not in sensitive parental cells (Fig. 4d,e and Supplementary Fig. 5j,k) . In MV4-11R cells, HOXB7 and HOXA9 mRNA and protein expression were suppressed by bortezomib treatment (Supplementary Fig. 5l,m) . NF-κB did not play a role in either the resistance mechanism or the bortezomib response of MV4-11R cells (Supplementary Fig. 5n ).
Restoration of EZH2 protein improves drug sensitivity in AML patient samples
We hypothesized that bortezomib treatment could overcome drug resistance in AML by inhibition of EZH2 degradation, and we therefore analyzed the response to bortezomib of primary AML cells in vitro. Low-dose bortezomib treatment increased EZH2 protein levels in five out of ten AML patient samples from diagnosis and relapse (Fig. 4f) . Increased cytotoxic efficacy of the combination of AraC and bortezomib was predominantly restricted to blasts from patients with increased EZH2 levels after bortezomib exposure ( Fig. 4g and Supplementary Figs. 6a and 7a) . These blasts also showed decreased HOX gene expression after bortezomib treatment ( Fig. 4h and Supplementary Fig. 6b and 7b) . Clinical characteristics and cytogenetic findings did not differ between bortezomibresponsive and bortezomib-non-responsive patients (Supplementary bortezomib exposure (average 2.6 mutations per patient) (P = 0.073, Mann-Whitney test). In FLT3-ITD-positive AML blasts, bortezomib pretreatment did increase EZH2 levels and sensitivity to AraC ( Fig. 4f and Supplementary Fig. 6a ) and also to PKC412 (Fig. 4i) .
We then focused on one of the tested AML patients (UPN14009), who had meanwhile suffered from a third relapse after a second allogeneic hematopoietic stem cell transplantation (alloHSCT) and for whom treatment options had been exhausted. Ex vivo treatment with either bortezomib or the second-generation proteasome inhibitor carfilzomib induced an increase of EZH2 protein, and a solid response to proteasome inhibitors in combination with AraC was observed (Fig. 5a) . Primary AML blasts from this patient contained a complex of CDK1-phospho-Thr487-EZH2-HSP90 as analyzed by co-IP and western blotting (Fig. 5b) . In contrast, the complex was not observed in primary AML blasts that did not show a bortezomibinduced increase of EZH2 protein (Fig. 5b) . Nuclear phosphorylated p65, a marker for active NF-κB signaling, was not detectable in the blasts of patient 14009 (Fig. 5c) . Based on the observed ex vivo responses, the patient was treated with a therapeutic dose of bortezomib (1.3 mg/m 2 subcutaneously) at days 1 and 5 plus 3 g/m 2 AraC twice daily at days 1, 3 and 5. Three hours after the initial bortezomib dose, EZH2 protein levels increased in the patient's blasts (Fig. 5d) in conjunction with a subsequent decrease of HOXA9 protein levels (Fig. 5d) , providing a proof of activity of bortezomib in an AML patient through increasing the stability of EZH2 in vivo. The treatment resulted in a clearance of blasts from the peripheral blood and a significant reduction of CD34 + GPR56 + blasts, representing the more immature blast population 37 (Fig. 5e) . In addition, the treatment with bortezomib plus AraC induced a more rapid decrease of leukocytes and blasts than most of the conventional chemotherapies applied at diagnosis and former relapses of the patient (Fig. 5f) .
Blasts from a second AML patient with early relapse on day 240 after allogeneic transplant showed an increase in EZH2 protein levels after in vitro exposure to bortezomib with increased sensitivity to AraC (Fig. 5g) . Upon treatment with bortezomib and AraC, the patient achieved a second remission with complete blast clearance and 100% donor chimerism (Fig. 5h,i) . The patient then underwent a second allogeneic transplant and continued to be in complete remission until the patient died due to graft-versus-host disease on day 174 after transplantation.
DISCUSSION
The histone methyltransferase EZH2 plays a complex role in cancer development, acting as either oncogene or tumor suppressor depending on cancer type. Although loss of EZH2 activity by inactivating mutations has been described as leading to poor prognosis in MDS and MDS/MPN, not much is known about the role of EZH2 in AML. Herein we found that low EZH2 protein levels are associated with poor survival in AML, and that loss of EZH2 induces resistance toward multiple drugs, including TKIs. We also showed that loss of EZH2 protein occurs in about 45% of relapsed AML samples. Here, decreased levels of EZH2 protein frequently depended on post-translational deregulation of EZH2 protein. The loss of EZH2 mediated by the CDK1-HSP90 interaction followed by proteasomal degradation constitutes an epigenetic pathway of drug resistance in AML via deregulation of HOX gene expression (Fig. 6) . Several other mechanisms have been reported to decrease EZH2 mRNA and/or protein levels in AML, such as 7/7q chromosomal deletions, since EZH2 is located on chromosome 7q36.1. Further, splicing dysfunction by mutations in spliceosomal genes such as U2AF1 or SRSF2 has been shown to decrease EZH2 mRNA levels in about 10-25% of AML patients 38, 39 . In AML and MDS, patients with −7/del7q are largely refractory to chemotherapy and have a particularly poor prognosis 20, 40 . U2AF1 and SRSF2 mutations also have been shown to be associated with an adverse outcome 41, 42 , and U2AF1 and inactivating EZH2 mutations are mutually exclusive 38 . The results from our study, demonstrating that loss of EZH2 induces drug resistance, may provide a possible explanation for the poor prognosis of patients with −7/del7q or spliceosomal mutations.
The epigenetic mechanism of drug resistance that we describe here can be overcome by inhibiting CDK1, HSP90 or the proteasome. Notably, in a recent clinical trial the addition of bortezomib to AraC and daunorubicin in induction therapy has been shown to be feasible with a remission frequency of 65% in unselected older patients 43 . Accordingly, inhibition of EZH2 degradation in combination with chemotherapy and/or TKIs may be a promising therapy concept in drug-resistant AML.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. Resistance genes: Hox genes, transporter genes, others Figure 6 Proposed model for EZH2-controlled drug resistance in AML cells. In resistant cells EZH2 is phosphorylated at Thr487 by CDK1, which is stabilized by the STIP1 and HSP90 proteins. Phosphorylation of Thr487 leads to enhanced binding and activity of E3 ubiquitin protein ligases such as TRIM21, ubiquitination of EZH2 and degradation by the proteasome. EZH2 then no longer introduces H3K27me3 at promoters of resistance genes such as HOXB7, HOXA9 or ABCC1, which become transcriptionally active. EZH2 degradation can be inhibited by proteasome inhibitors as well as HSP90 or CDK1 inhibitors, which increase EZH2 protein levels, inactivate expression of resistance genes and restore drug sensitivity (P, phosphorylation; Ub, ubiquitination). PKC412 (Midostaurin), CEP-701 (Lestaurtinib), bortezomib (Velcade) and carfilzomib (Kyprolis) were purchased from LC Laboratories (Woburn, MA). ABT-869 (Linifanib) and DZNep were purchased from Cayman Chemicals (Ann Arbor, MI). Cytarabine (AraC) and daunorubicin were obtained from Sigma Aldrich (Taufkirchen, Germany). CGP74514A, CDK1-Inhibitor III and SAH-EZH2 were purchased from Merck Millipore (Schwalbach, Germany). AC220 (Quizartinib) and AT13387 (Onalespib) were purchased from SelleckChem (Houston, TX). GSK126 was obtained from Biovision (Milpitas, CA). Treatment of patients with bortezomib was performed after informed consent on the off-label use following the Principles of Helsinki.
ONLINE METHODS
Cultivation of primary cells. Primary AML cells were cultured as published 45 .
Treatment with EZH2 inhibitors. Drug-sensitive MV4-11 cells were treated for 7 days with 10 µM of SAH-EZH2 or 3 µM GSK126, respectively, as described previously 46 . The SAH-EZH2 peptide disrupts the interaction of EZH2 and EED thereby reducing EZH2 protein levels whereas GSK126 inhibits the methyltransferase activity of EZH2 (ref. 46) . Exposure of sensitive MV4-11 cells and patient samples to 1 µM of DZNep was conducted for 24 h.
Cell viability assays. Leukemic cell lines were seeded in 96-well culture plates at a density of 2.5 × 10 4 viable cells/100 µl/well in triplicates and were treated with FLT3-inhibitors or standard chemotherapeutics at the indicated concentrations. Colorimetric CellTiter 96 AQueous One Solution Cell Proliferation assay (Promega, Madison, WI) was used to determine the cytotoxicity. IC 50 values were calculated with GraphPad Prism software (San Diego, CA). Experiments were performed in triplicate.
Viability of primary AML cells was determined by trypan blue staining and cell counting or Acridine Orange/PI staining and cell counting, respectively.
Western blot analysis. Cells were lysed in RIPA lysis buffer (50 mM Tris-HCL [pH 8], 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, protease inhibitors) for 30 min at 4 °C. Protein extracts were resolved by SDS-PAGE and blotted to nitrocellulose membranes and probed with the following antibodies: anti-β-actin (Sigma-Aldrich, A5441, 1:5,000), anti-EZH2 (AC22, Cell Signaling Technology, 3147S, 1:1,000), anti-EZH2 (D2C9, Cell Signaling, 5246, 1:1,000), anti-pT487 EZH2 (Abcam, ab109398, 1:1,000), anti-SUZ12 (Cell Signaling Technology, 3737S, 1:1,000), anti-EED (Millipore, 09-774, 1:1,000), anti-EZH1 (Abcam, ab13665, 1:1,000), anti-total H3 (Abcam, ab39763, 1:5,000), anti-H3K27me3 (Cell Signaling Technologies, 9733, 1:2,000), anti-V5 (Abcam, ab9116, 1:1,000), anti-total CDK1 (Cell Signaling Technologies, 9112S, 1:1,000), anti-pCDK1 (Cell Signaling Technologies, 9111S, 1:1,000), anti-MRP1/ABCC1 (Santa Cruz, sc-18835, 1:500), anti-Ubiquitin (Abcam, ab7780, 1:1,000), anti-HOXB7 (Abcam, ab51237, 1:1,000), anti-HOXA9 (Abcam, ab140631, 1:1,000), anti-TRIM21 (Abcam, ab91432, 1:1,000), anti-HSP90 (Abcam, ab13495, 1:1,000) and anti-STIP1 (Abcam, ab126724, 1:1,000). Each primary antibody used has been validated for the relevant species and applications by the manufacturer.
Densitometric analysis was performed using ImageJ software (NIH, Bethesda, MD).
Immunoprecipitation and co-immunoprecipitation. For EZH2-IPs a five-fold excess of resistant IP-lysate was used to normalize IPs for reduced EZH2 levels in resistant cells. Immunoprecipitation of EZH2 or Ubiquitin was performed using Dynabeads Protein G Immunoprecipitation Kit (Life Technologies, Darmstadt, Germany) according to manufacturer's instructions using following antibodies: rabbit IgG control (Cell Signaling), anti-EZH2 (DC29, Cell Signaling) and antiUbiquitin antibody (Abcam, ab7780).
Co-Immunoprecipitation of the CDK1/EZH2/STIP1/HSP90 interaction was performed using Dynabeads Co-Immunoprecipitation Kit (Life Technologies, Darmstadt, Germany).
Analysis of post-translational modifications of EZH2 by Mass Spectrometry (MS).
Immunoprecipitation of EZH2 using cell lysates from sensitive and resistant cells was performed using Sepharose Beads Immunoprecipitation Kit (Biovision, Milpitas, CA) according to manufacturer's instructions using following antibodies: anti-EZH2 (DC29, Cell Signaling) and anti-pT487 EZH2 (Abcam, ab109398). The corresponding protein bands on the SDS-PAGE containing EZH2 were cut off and sliced into small gel pieces for following in-gel digestion. After two-times of washes with 25 mM ammonia bicarbonate buffer, gel slices were reduced with dithiothreitol, alkylated with 2-iodoacetamide and digested with trypsin overnight. The resulting peptide mixtures were then extracted and dried in a SpeedVac as described previously 47 .
For phosphopeptide enrichment, digested peptides were re-suspended in loading buffer (80% acetonitrile (ACN), 5% trifluoroacetic acid (TFA), 5% glycerol) and loaded onto a pre-equilibrated self-packed TiO 2 spin column (5 µm, GL Science, Japan) twice by centrifugation. The TiO 2 beads were then sequentially washed with three times of loading buffer, three times of 80% ACN, 5% TFA and one time with 60% ACN, 0.1% TFA. Phosphopeptides were eluted with 0.5 N NH 4 OH (pH ≥10.5) and dried in a SpeedVac (Thermo Fisher Scientific) as described previously 47 .
LC-MS/MS analysis was performed on a Q Exactive HF mass spectrometer (Thermo Fisher Scientific, USA) coupled with an Ultimate 3000 RSLC system (Dionex, USA). Phosphopeptides were first enriched on a self-packed precolumn (100 µm × 3 cm, Reprosil-Pur120 C18-AQ 3 µm, Dr. Maisch GmbH, Germany) and then separated on an analytical column (75 µm × 35 cm, ReproSil-Pur 120 C18-AQ, 1.9 µm, Dr. Maisch GmbH) with a 40-min linear gradient of 2-40% buffer B (80% ACN, 0.1% formic acid (FA)) mixed with corresponding composition of buffer A (0.1% FA in water) at a constant flow rate of 300 nl/min. The Q Exactive HF was operated in a data-dependent acquisition mode where one full MS scan across the 350-1,600 m/z range was acquired at a resolution setting of 120,000 FWHM (full width, half maximum) to select up to 20 most abundant peptide precursors of charge states 2-6 above a 3 × 10 4 intensity threshold, at an isolation width of 1.4 m/z. Precursors were fragmented by Higher Collision Energy Dissociation (HCD) with nitrogen at a normalized collision energy setting of 28%, and their product ion spectra were recorded with a start mass of 110 m/z at resolution of 30,000 FWHM. Automatic gain control target value and maximum ion injection times for MS and MS/MS were 1 × 10 6 in 50 ms, and 1 × 10 5 in 64 ms, respectively. Selected precursor m/z values were then excluded for the following 30 s.
The MS raw files were processed by MaxQuant 48 (version 1.5.2.8) and MS/MS spectra were searched against UniProt human database (downloaded on Feb, 2015; 89,796 entries) via the Andromeda search engine 49 . Mass tolerance after recalibration of precursor mass and fragment ion mass were set as 6 and 20 ppm, respectively. Allowed variable modifications included protein deamidation (N), oxidation (M) and phosphorylation (STY). Cysteine carbamidomethylation was defined as a fixed modification. Minimal peptide length was set to 7 amino acids with the maximum of two enzymatic mis-cleavages. The false discovery rate (FDR) was set to 1% for both peptide and protein identifications. Intensities of all identified peptides were determined by the MaxQuant with the option of "match between runs" on.
Identification of interaction partners of EZH2 using SILAC-immunoprecipitation quantitative proteomics. MV4-11 and MV4-11R cells were each cultured in medium containing arginine and lysine labeled with heavy (H) or light (L) isotopes (SILAC medium, Thermo Scientific, Rockford, USA), respectively, for a total of 5 cell passages. Protein extracts were prepared and immunoprecipitation was performed using either anti-total EZH2/anti-pT487 EZH2 antibody (heavylabeled extracts) or beads only (light-labeled extracts) for sensitive and resistant cells, respectively. A five-fold excess of resistant IP-lysate was used to normalize IPs for reduced EZH2 levels in resistant cells. IPs were performed from two cell culture replicates. The beads were resuspended in 50 µl NuPAGE LDS Sample buffer (Invitrogen, Carlsbad, CA, USA) supplemented with 0.1 M DTT. After denaturation for 10 min at 95 °C, the denatured H-and L-labeled proteins were pooled in equimolar amounts and subsequently the samples were separated by size using an 1D-PAGE (Invitrogen, Carlsbad, CA, USA) followed by Coomassie blue staining. Each gel lane was cut into 23 gel slices. Proteins from each slice were in-gel digested with trypsin (Promega, Madison, WI) according to the protocol described 50 . MS measurements were carried out using a nanoflow HPLC (Agilent, Boeblingen, Germany) coupled to a nanoelectrospray Q exactive HF mass spectrometer (Thermo Fisher Scientific, Waltham, MA) as previously described 51 . A lentiviral expression vector containing a shRNA against TP53 was purchased from Addgene (shp53 pLKO.1 puro, Plasmid 19119). The pLKO.1 scrambled control was also ordered from Addgene (Plasmid 1864).
Cloning
For overexpression of WT and mutant T487A EZH2, pTYF Vectors containing WT EZH2, and EZH2 T487A coding sequence were kindly donated by the lab of Y. Zhang (Chapel Hill, NC) and coding regions were subcloned into pCDH lentiviral expression vector (System Biosciences, Mountain View, CA) according to manufacturer's instructions introducing a V5 tag at the 3′ end of the EZH2 sequence. All constructs were verified by DNA sequencing.
For generation of the FLT3-ITD-N676K overexpression lentivector, RNA was isolated from sensitive MV4-11 and reverse transcribed using SuperScript (Life Technologies, Darmstadt, Germany). The coding region of FLT3, harboring the ITD mutation, was amplified from the cDNA introducing a V5 tag at the 3′ end. The amplified sequence was introduced into TOPO Cloning Vector and site directed mutagenesis was performed using Quick Change Kit (Promega, Mannheim, Germany). The construct was verified by DNA sequencing for existence of N676K mutation before PCR-based cloning into pCDH lentiviral expression vector.
Lentiviral vectors expressing shRNAs directed against HOXB7 and HOXA9 were purchased from abm Good (Richmond, Canada). EZH2 codon usage adaption was performed using GENEius and the resulting sequence was synthesized and cloned into pCDH at Eurofins (Penzberg, Germany). Lentiviral transfection and transduction. HEK293T cells were transfected with 10 µg of lentiviral plasmid and ViraPower helper plasmids (Life Technologies, Darmstadt, Germany) using TurboFect transfection Reagent (Thermo Fisher Scientific, Schwerte, Germany). Supernatants containing viral particles were harvested 48 and 72 h after transfection and virus particles were precipitated by ultracentrifugation. Lentiviral transduction of human cell lines was performed in the presence of 8 µg/ml polybrene (Sigma-Aldrich, Taufkirchen, Germany).
FACS-based assays. Drug efflux assay. Activity of drug transporters P-gp, MRP1 and BCRP was flow cytometrically analyzed by use of eFLUXX-ID Multidrug Resistance Assay Kit (Enzo Life Sciences, Lörrach, Germany).
Cell cycle analysis via BrdU. For cell cycle analysis AML cells were synchronized by serum starvation for 24 h. Upon release cells were incubated with 10 µM BrDU for 1 h, washed in PBS and stained with anti-BrdU-FITC and propidium iodide (PI) according to the manufacturer's instructions (BD Pharmingen, San Diego, CA). Analysis was performed using a BD LSR Fortessa cytometer (BD Biosciences, San Jose, CA).
Ki67 staining. To determine the proliferative index AML cell lines were stained using the PE Mouse Anti-Ki67 Set (BD Pharmingen, San Diego, CA) according the manufacturer's instructions. Analysis was performed using a BD LSR Fortessa cytometer (BD Biosciences, San Jose, CA).
CDK1 kinase activity assay. Analysis of CDK1 activity was performed by using MESACUP Cdc2/Cdk1 Kinase Assay Kit according to manufacturer's instructions (MBL International, Woburn, MA).
Immunohistochemistry. For tissue microarray (TMA) preparations, bone marrow trephines were obtained from 136 patients with newly diagnosed AML. Bone marrow trephines were formalin-fixed and paraffin-embedded. Written informed consent was obtained from all patients and the study was approved by the local Institutional Review Board. Only patients treated at the University Hospital of Münster and with available clinical follow-up data were included. The study was in compliance with all applicable national and local ethics guidelines. Only patients receiving intensive treatment were included in further analysis (n = 124). Preparation of TMAs and staining was performed as previously described 52 . For staining following antibodies were used: EZH2 (Cell Signaling Technologies, #3147) and H3K27me3 (Active Motif, #39155). As the range of the blast percentage in individual bone marrow trephines was diverse (ranging from 20-99%) EZH2 expression was only scored in the blast cells, not in normal hematopoietic cells. The staining intensity of blasts was scored 0 (no staining), 1 (weak staining), 2 (moderate staining) or 3 (strong staining) according to Remmele's Immunoreactive Score (IRS) 53 . To discriminate between low and high EZH2 expression scores 0 and 1 were considered as low, scores 2 and 3 were considered as high expression. Clinical data of patients are given in Supplementary Table 1. Xenograft mouse models. NOD.Cg-Prkdc scid IL2rg tm1Wjl /SzJ (NSG; Charles River Laboratories, Sulzfeld, Germany) were maintained under specific pathogen-free conditions in the research animal facilities of the Helmholtz Center Munich, Germany and of the University Hospital Halle (Saale), Germany. Animals had free access to food and water, and were housed with a 12-h light-dark cycle and constant temperature. NSG animal trials were performed in accordance with the current ethical standards of the official committee on animal experimentation (written approval by Regierung von Oberbayern and Landesverwaltungsamt Sachsen-Anhalt, Germany). Animals that lost more than 15% of their body weight during treatment course were euthanized as per institutional policy. For all animal studies no blinding was performed. No statistical method was used to predetermine sample size.
5 × 10 6 MV4-11 shControl and MV4-11 shEZH2#2 cells expressing a recombinant codon-optimized form of firefly luciferase were transplanted via tail-vein injection into sublethally irradiated 16-week-old female NSG mice.
